ETOILE: Real-World Evidence of 24 Months of Ranibizumab 0.5 mg in Patients with Visual Impairment Due to Diabetic Macular Edema-Reference-Cited by-同舟云学术

ETOILE: Real-World Evidence of 24 Months of Ranibizumab 0.5 mg in Patients with Visual Impairment Due to Diabetic Macular Edema

Published:2021-06 Issue: Volume:Volume 15 Page:2307-2315
ISSN:1177-5483
Container-title:Clinical Ophthalmology
language:en
Short-container-title:OPTH

Author:

Kodjikian Laurent,Lecleire-Collet Amelie,Dot Corinne^ORCID,Le Lez Marie-Laure,Baillif Stéphanie,Erginay Ali,Souied Eric,Fourmaux Eric,Gain Philippe,Ponthieux Anne

Publisher

Informa UK Limited

Subject

Ophthalmology

Reference24 articles.

1. The 25-Year Incidence of Visual Impairment in Type 1 Diabetes Mellitus

2. Ten-year Incidence of Visual Loss in a Diabetic Population

3. Global Prevalence and Major Risk Factors of Diabetic Retinopathy

4. Safety and Efficacy of Ranibizumab in Diabetic Macular Edema (RESOLVE Study)

5. Ranibizumab 0.5 mg treat-and-extend regimen for diabetic macular oedema: the RETAIN study

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. From randomised controlled trials to real-world data: Clinical evidence to guide management of diabetic macular oedema;Progress in Retinal and Eye Research;2023-11

2. Management of diabetic macular oedema in France from 2012 to 2018: The nationwide LANDSCAPE study;Acta Ophthalmologica;2023-10-24

3. Real-World Outcomes of Anti-VEGF Therapy in Diabetic Macular Oedema: Barriers to Treatment Success and Implications for Low/Lower-Middle-Income Countries;Ophthalmology and Therapy;2023-02-23

4. Do new drugs for diabetic macular edema offer a safer option?;Expert Opinion on Drug Safety;2022-12-02